Canada Considers Performance-Based Outcome Reimbursement Deals For Oncology Drugs
Executive Summary
Manufacturers selling oncology drugs in Canada could soon face group price negotiations and performance-based reimbursement agreements as authorities in the country plan to improve access to oncology drugs.
You may also be interested in...
Multi-Company Product Listing Agreements On The Rise In Canada
The pan-Canadian Pharmaceutical Alliance has negotiated product listing agreements with three hepatitis C drug makers in one of its first major negotiations with multiple manufacturers. The pCPA may want to negotiate more deals with several companies at once, particularly those with drugs in crowded markets.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.